Wall Street brokerages predict that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will post earnings per share of ($0.23) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.14). Alpine Immune Sciences reported earnings of ($0.62) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 62.9%. The business is expected to announce its next quarterly earnings report on Wednesday, November 11th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.70) to ($1.08). For the next financial year, analysts expect that the business will report earnings of ($0.62) per share, with EPS estimates ranging from ($1.37) to $0.14. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.30). Alpine Immune Sciences had a negative net margin of 1,120.46% and a negative return on equity of 125.54%. The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $2.13 million.
Several analysts recently issued reports on the stock. ValuEngine downgraded shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Piper Sandler reduced their price target on shares of Alpine Immune Sciences from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Oppenheimer reissued a “buy” rating and issued a $19.00 price target on shares of Alpine Immune Sciences in a research report on Wednesday, August 12th. Zacks Investment Research raised shares of Alpine Immune Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Finally, Cowen started coverage on shares of Alpine Immune Sciences in a report on Wednesday, August 26th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.00.
NASDAQ ALPN opened at $8.72 on Tuesday. The company has a fifty day simple moving average of $8.18 and a 200 day simple moving average of $6.88. Alpine Immune Sciences has a 12-month low of $2.05 and a 12-month high of $15.00. The company has a current ratio of 3.24, a quick ratio of 3.24 and a debt-to-equity ratio of 0.61. The company has a market cap of $207.41 million, a P/E ratio of -4.90 and a beta of 1.18.
Institutional investors and hedge funds have recently bought and sold shares of the business. Berman Capital Advisors LLC bought a new position in Alpine Immune Sciences in the second quarter worth $529,000. Ikarian Capital LLC bought a new position in Alpine Immune Sciences in the second quarter worth $46,000. Finally, Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in Alpine Immune Sciences by 70.1% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 17,013 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 7,013 shares in the last quarter. 29.95% of the stock is currently owned by hedge funds and other institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Read More: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.